399-95-1Relevant articles and documents
A potent free fatty acid receptor 1 agonist with a glucose-dependent antihyperglycemic effect
Wang, Xuekun,Xu, Yurui,Feng, Shujun,Huang, Xinyu,Meng, Xia,Chen, Jiao,Guo, Leilei,Ge, Junliang,Zhang, Jikang,Chen, Jianmei,Cheng, Li,Gu, Kai,Zhang, Yu,Jiang, Qing,Ning, Xinghai
, p. 8975 - 8978 (2019)
We present a novel free fatty acid receptor 1 (FFA1) agonist, named PAFA, with a strong agonist potency (EC50 = 6.04 nM) and good serum stability. PAFA significantly stimulates insulin secretion in INS-1 cells in a glucose-dependent manner and exhibits high antihyperglycemic effects in db/db mice without adverse effects.
Regorafenib analogues and their ferrocenic counterparts: Synthesis and biological evaluation
Wilde, Myron,Arzur, Danielle,Baratte, Blandine,Lefebvre, Dorian,Robert, Thomas,Roisnel, Thierry,Le Jossic-Corcos, Catherine,Bach, Stéphane,Corcos, Laurent,Erb, William
supporting information, p. 19723 - 19733 (2020/12/04)
Approved by the FDA in 2012, regorafenib is one of the last chance treatments for colorectal cancer. While various analogues have already been prepared, ferrocenic derivatives have never been evaluated. In this study, we prepared various ferrocene-containing derivatives of regorafenib and recorded their biological activity in kinase and cellular assays. This led to the identification of a squaramide derivative which shows a good cellular activity and three ferrocene analogues with promising activity in both kinase and cellular assays. This journal is
A new pathway via intermediate 4-amino-3-fluorophenol for the synthesis of regorafenib
Du, Fangyu,Zhou, Qifan,Shi, Yajie,Yu, Miao,Sun, Wenjiao,Chen, Guoliang
, p. 576 - 586 (2019/02/01)
A practical synthetic route to regorafenib, in which the target compound was obtained via a 10-step synthesis starting from 2-picolinic acid, 4-chloro-3-(trifluoromethyl)aniline, and 3-fluorophenol, is reported. Crucial to the strategy is the preparation of 4-amino-3-fluorophenol via Fries and Beckman rearrangements using an economical and practical protocol. The main advantages of the route include inexpensive starting materials and an acceptable overall yield. A scale-up experiment was carried out to provide regorafenib with 99.96% purity in 46.5% total yield.